9d ago
Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function
Dyer · B. P. · Deery · M. · Heyman · R. · Robinson · P. · +8 more
Abstract
Background Elexacaftor-tezacaftor-ivacaftor (ETI) has been demonstrated to improve lung function in clinical trials; however, evidence describing effects on trajectories and whether long-term improvements are sustained (>1-year) is lacking. We estimated within-person lung clearance index (LCI) trajectories before and after ETI initiation, assessing changes in level and rate of change, alongside acute LCI change, up to three years after ETI initiation. Methods Prospective observational study of c
Discussion · 0
Sign in to join the discussion.